Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing
Published in: Leukemia
Access to document
10.1038/leu.2014.201
document
Y. Liu, F.R. Abdul Razak, M. Terpstra, F.C. Chan, A. Saber, M. Nijland, G. van Imhoff, Lydia Visser, R. Gascoyne, C. Steidl, J. Kluiver, A. Diepstra, K. Kok, Anke van den Berg
False positive spinal cord uptake on fluorodeoxyglucose positron-emission tomography following treatment of lymphoma
Published in: British Journal of Haematology
Access to document
10.1111/bjh.12057
Marcel Nijland, Max Beijert, Alfons H. H. Bongaerts, Adrienne H. Brouwers
Adrenal Hemorrhage Causing Adrenal Insufficiency in a Patient with Antiphospholipid Syndrome: Increased Adrenal F-18-FDG Uptake
Published in: Journal of Clinical Endocrinology and Metabolism
Access to document
10.1210/jc.2012-2050
Leo Boneschansker, Marcel Nijland, Andor W J M Glaudemans, Sibylle B van der Meulen, Philip M Kluin, Robin P F Dullaart